Who are Kineret® (Anakinra)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Anakinra (r-metHuIL-1ra), Anakinra (Kineret®), Kineret, Anakinra.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/kineret-anakinra.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Kineret® (Anakinra) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Kineret® (Anakinra) (Kineret® (Anakinra)) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Interleukin-1 receptor antagonist. Area: Immunology.

marketed Interleukin-1 receptor antagonist IL-1 receptor type I Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Kineret® (Anakinra) (Kineret® (Anakinra)) — Amgen. Anakinra is a recombinant interleukin-1 receptor antagonist that blocks IL-1 signaling to reduce inflammation.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Kineret® (Anakinra) TARGET	Kineret® (Anakinra)	Amgen	marketed	Interleukin-1 receptor antagonist	IL-1 receptor type I
Anakinra (r-metHuIL-1ra)	Anakinra (r-metHuIL-1ra)	Amgen	marketed	IL-1 receptor antagonist	IL-1 receptor type I (IL-1RI)
Anakinra (Kineret®)	Anakinra (Kineret®)	Monash Medical Centre	phase 3	IL-1 receptor antagonist	IL-1 receptor type I
Kineret	ANAKINRA	Biovitrum Ab	marketed	Interleukin-1 Receptor Antagonist [EPC]	Interleukin-1 receptor, type I	2001-01-01
Anakinra	Kineret	Biovitrum Ab	marketed	Interleukin-1 Receptor Antagonist	Interleukin-1 receptor, type I	2001-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Interleukin-1 receptor antagonist class)

Amgen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Kineret® (Anakinra) — Competitive Intelligence Brief. https://druglandscape.com/ci/kineret-anakinra. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab